Skip to main content
Isofol Medical logo

Isofol Medical — Investor Relations & Filings

Ticker · ISOFOL ISIN · SE0009581051 LEI · 549300MCXYAHG7VBHX75 ST Professional, scientific and technical activities
Open in API
Filings indexed 208 across all filing types
Latest filing 2024-07-16 Regulatory Filings
Country SE Sweden
Listing ST ISOFOL

About Isofol Medical

https://isofolmedical.com/

Isofol Medical is a clinical-stage biotechnology company dedicated to improving treatments for severe forms of cancer. The company's primary focus is the development of its lead drug candidate, arfolitixorin. This next-generation, folate-based therapy is designed to enhance the efficacy of standard cancer treatments, such as chemotherapy. Arfolitixorin is the active metabolite of commonly used folate-based drugs, potentially offering a therapeutic benefit to a broader patient population by bypassing complex metabolic activation steps. The company's goal is to help more patients respond better to their treatment, thereby improving their prognosis.

Recent filings

Filing Released Lang Actions
Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin
Regulatory Filings Classification · 95% confidence The document is a press release announcing new preclinical data supporting the clinical development plan for a drug candidate (arfolitixorin). It details scientific findings, mentions future clinical studies, and includes standard boilerplate information about the company and contact details. Crucially, it ends with a statement: "Detailed study data will be published in the form of abstracts and/or other scientific publications." This indicates the document itself is an announcement of scientific progress, not the final detailed report (like an AR or 10-K) or a formal regulatory filing for a specific event like a dividend or management change. Since it is an announcement related to scientific/clinical progress and future plans, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate update, or potentially an Investor Presentation (IP) if it were structured as slides, but as a press release detailing scientific progress, RNS is the most appropriate general category for non-standard, material corporate news that isn't explicitly covered elsewhere. Given the context of financial reporting databases, this type of scientific update is often categorized broadly.
2024-07-16 English
Isofol meddelar att nya prekliniska data stöder den tidigare annonserade kliniska utvecklingsplanen för arfolitixorin
Regulatory Filings Classification · 90% confidence The document is a press release dated July 16, 2024, announcing positive preclinical data supporting the clinical development plan for their drug candidate, arfolitixorin. It details study results, mentions collaboration with a university hospital (Charité), and quotes the CEO. Crucially, the final paragraph states: "Mer utförliga studiedata kommer att publiceras i form av abstracts och/eller andra vetenskapliga publikationer." (More detailed study data will be published in the form of abstracts and/or other scientific publications.) Furthermore, the document is short (4647 characters) and functions as an announcement about ongoing or future scientific/clinical activities, rather than a comprehensive financial report (like 10-K or IR) or a formal regulatory filing detailing insider trades or capital changes. Since it is an announcement regarding scientific/clinical progress that doesn't fit the specific categories like ER, IR, or CAP, and it is not a formal regulatory filing announcing the publication of a major report (RPA), the most appropriate general category for a significant, non-financial, non-meeting-related corporate update that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for corporate news releases. However, upon re-evaluating the definitions, this document is a specific corporate announcement about R&D progress and future clinical plans. It is not a standard earnings release (ER), interim report (IR), or a notice of a dividend (DIV). It is not a proxy statement (PSI) or a management discussion (MDA). Given the content focuses on scientific data supporting future clinical trials, it is a general corporate update. Since RNS is the fallback for miscellaneous filings, and this is a press release announcing scientific progress, RNS is the best fit among the provided options, as it is not a specific financial or governance report.
2024-07-16 Swedish
Isofol announces a post hoc per-protocol analysis of the AGENT study, further supporting arfolitixorin’s continued clinical development
Investor Presentation Classification · 92% confidence The document is a press release dated July 5, 2024, announcing the results of a 'post hoc per-protocol analysis' of the clinical phase III study AGENT concerning the drug arfolitixorin. It discusses clinical data, efficacy rates (ORR), statistical differences, and future development plans (Phase Ib/II study). This content is characteristic of an announcement detailing recent scientific or clinical findings intended for investors, often released before a formal comprehensive report. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR). It is also not a transcript (CT) or a formal regulatory filing like a DVA or DIRS. Since it is a detailed announcement of clinical results and analysis supporting future strategy, it aligns best with an Investor Presentation (IP) or a detailed Earnings Release (ER) if it were quarterly. Given the focus on clinical data analysis supporting the drug's continued development, it functions as a key piece of investor communication. However, the document structure is that of a press release announcing specific scientific findings and their implications for future trials, which is a common format for communicating significant clinical milestones to investors. While it contains detailed analysis, it is an announcement/release rather than a formal, structured report like a 10-K or IR. It is most closely related to the type of information shared in an Investor Presentation (IP) or a detailed Earnings Release (ER). Since it is a press release announcing specific results and outlook, and not a formal financial report, 'ER' (Earnings Release) is often used for significant periodic announcements, but 'IP' (Investor Presentation) captures the nature of presenting detailed clinical data analysis to support investment decisions. Given the depth of the analysis provided (details on patient exclusion criteria, ORR percentages, regional differences), it goes beyond a typical brief ER highlight. It functions as a detailed update on the asset's progress, which is a core component of investor relations material. I will classify it as an Investor Presentation (IP) as it presents detailed analytical findings to support the investment case for the drug candidate's continued development.
2024-07-05 English
Isofol meddelar att en post hoc-analys per protokoll av AGENT-studien ger ytterligare stöd för arfolitixorins fortsatta kliniska utveckling
Regulatory Filings Classification · 95% confidence The document is a press release from Isofol Medical AB, dated July 5, 2024, announcing the results of a post hoc analysis of their Phase III AGENT study regarding their drug arfolitixorin. It details clinical findings, future development plans (Phase Ib/II study), and mentions collaboration agreements. The text explicitly states that the information is intended for investors and is being made public under EU market abuse regulations. This type of announcement, focusing on significant clinical trial results and strategic updates intended for the market, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a detailed announcement of new clinical data and strategic direction, rather than just a brief notification of a report's publication (RPA), and it contains key financial/operational highlights, ER is a strong candidate. However, given the specific nature of reporting clinical trial outcomes and strategic direction updates that aren't strictly quarterly earnings figures, it often falls under a general regulatory announcement category if a more specific one like 'Clinical Trial Update' isn't available. Comparing the definitions, 'ER' (Earnings Release) is for initial announcements of periodical financial results (key highlights only). This is a clinical/strategic update, not a standard quarterly earnings report. 'RNS' (Regulatory Filings) is the fallback for miscellaneous filings. Since this is a significant, market-moving announcement detailing clinical data and future strategy, and it doesn't fit perfectly into ER (which usually focuses on revenue/profit), 'RNS' is the most appropriate general regulatory category for this type of corporate disclosure that isn't a formal statutory report (like 10-K or IR).
2024-07-05 Swedish
Isofols Chief Financial Officer lämnar bolaget
Board/Management Information Classification · 99% confidence The document is a short press release announcing that the Chief Financial Officer (CFO), Magnus Hurst, is leaving the company in September due to family reasons (starting parental leave). This directly relates to a change in senior management. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is clearly an announcement of a management departure, not a full financial report, transcript, or legal filing.
2024-06-12 Swedish
Isofol's Chief Financial Officer to leave the company
Board/Management Information Classification · 99% confidence The document is a short press release announcing that the Chief Financial Officer (CFO), Magnus Hurst, is leaving the company in September. This directly relates to changes in senior management personnel. Based on the definitions, the 'Board/Management Information' category (Code: MANG) is the most appropriate classification for announcements of changes in senior management.
2024-06-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.